Visceral Pain in Preterm Infants with Necrotizing Enterocolitis: Underlying Mechanisms and Implications for Treatment

Overview

Journal Paediatr Drugs

Specialties Pediatrics
Pharmacology

Date 2025 Jan 3

PMID 39752054

Authors

Judith A Ten Barge

Gerbrich E van den Bosch

Rebeccah Slater

Nynke J van den Hoogen

Irwin K M Reiss

Sinno H P Simons

Affiliations

Soon will be listed here.

Abstract

Necrotizing enterocolitis (NEC) is a relatively rare but very severe gastrointestinal disease primarily affecting very preterm infants. NEC is characterized by excessive inflammation and ischemia in the intestines, and is associated with prolonged, severe visceral pain. Despite its recognition as a highly painful disease, current pain management for NEC is often inadequate, and research on optimal analgesic therapy for these patients is lacking. Insight into the mechanisms underlying intestinal pain in infants with NEC-visceral pain-could help identify the most effective analgesics for these vulnerable patients. Therefore, this comprehensive review aims to provide an overview of visceral nociception, including transduction, transmission, modulation, and experience, and discuss the implications for analgesic therapy in preterm infants with NEC. The transmission of visceral pain differs from that of somatic pain, contributing to the diffuse nature of visceral pain. Studies evaluating the effectiveness of analgesics for treating visceral pain in infants are scarce. However, research in visceral pain models highlights agents that may be particularly effective for treating visceral pain based on their mechanisms of action. Further research is necessary to determine whether agents that have shown promise for treating visceral pain in preclinical studies and adults are effective in infants with NEC as well.

References

Li Y, Dou Z, Yang L, Wang Q, Ni J, Ma J . Oxycodone versus other opioid analgesics after laparoscopic surgery: a meta-analysis. Eur J Med Res. 2021; 26(1):4. PMC: 7796650. DOI: 10.1186/s40001-020-00463-w. View

Palecek J, Paleckova V, Willis W . The roles of pathways in the spinal cord lateral and dorsal funiculi in signaling nociceptive somatic and visceral stimuli in rats. Pain. 2002; 96(3):297-307. DOI: 10.1016/S0304-3959(01)00459-6. View

Houghton L, Fell C, Whorwell P, Jones I, Sudworth D, Gale J . Effect of a second-generation alpha2delta ligand (pregabalin) on visceral sensation in hypersensitive patients with irritable bowel syndrome. Gut. 2007; 56(9):1218-25. PMC: 1954959. DOI: 10.1136/gut.2006.110858. View

Strigo I, Duncan G, Bushnell C, Boivin M, Wainer I, Rodriguez Rosas E . The effects of racemic ketamine on painful stimulation of skin and viscera in human subjects. Pain. 2005; 113(3):255-264. DOI: 10.1016/j.pain.2004.10.023. View

Norgren R, Smith G . Central distribution of subdiaphragmatic vagal branches in the rat. J Comp Neurol. 1988; 273(2):207-23. DOI: 10.1002/cne.902730206. View

Feng B, Gebhart G . Characterization of silent afferents in the pelvic and splanchnic innervations of the mouse colorectum. Am J Physiol Gastrointest Liver Physiol. 2010; 300(1):G170-80. PMC: 3025511. DOI: 10.1152/ajpgi.00406.2010. View

Dulai J, Smith E, Rahman T . Acid-sensing ion channel 3: An analgesic target. Channels (Austin). 2020; 15(1):94-127. PMC: 7801124. DOI: 10.1080/19336950.2020.1852831. View

Bhutta A . Ketamine: a controversial drug for neonates. Semin Perinatol. 2007; 31(5):303-8. DOI: 10.1053/j.semperi.2007.07.005. View

Hijma H, Siebenga P, de Kam M, Groeneveld G . A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Pharmacodynamic Effects of VX-150, a Highly Selective NaV1.8 Inhibitor, in Healthy Male Adults. Pain Med. 2021; 22(8):1814-1826. PMC: 8346919. DOI: 10.1093/pm/pnab032. View

10.

Houghton A, Wang C, Westlund K . Do nociceptive signals from the pancreas travel in the dorsal column?. Pain. 2001; 89(2-3):207-20. DOI: 10.1016/s0304-3959(00)00364-x. View

11.

Vuckovic S, Srebro D, Savic Vujovic K, Vucetic C, Prostran M . Cannabinoids and Pain: New Insights From Old Molecules. Front Pharmacol. 2018; 9:1259. PMC: 6277878. DOI: 10.3389/fphar.2018.01259. View

12.

Iftinca M, Defaye M, Altier C . TRPV1-Targeted Drugs in Development for Human Pain Conditions. Drugs. 2020; 81(1):7-27. DOI: 10.1007/s40265-020-01429-2. View

13.

Palazzo E, Luongo L, de Novellis V, Rossi F, Maione S . The Role of Cannabinoid Receptors in the Descending Modulation of Pain. Pharmaceuticals (Basel). 2016; 3(8):2661-2673. PMC: 4033943. DOI: 10.3390/ph3082661. View

14.

Davis A, Inturrisi C . d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther. 1999; 289(2):1048-53. View

15.

Riviere P . Peripheral kappa-opioid agonists for visceral pain. Br J Pharmacol. 2004; 141(8):1331-4. PMC: 1574907. DOI: 10.1038/sj.bjp.0705763. View

16.

OMara K, Gal P, Wimmer J, Ransom J, Carlos R, Dimaguila M . Dexmedetomidine versus standard therapy with fentanyl for sedation in mechanically ventilated premature neonates. J Pediatr Pharmacol Ther. 2012; 17(3):252-62. PMC: 3526929. DOI: 10.5863/1551-6776-17.3.252. View

17.

de Kort A, Joosten E, Patijn J, Tibboel D, van den Hoogen N . The development of descending serotonergic modulation of the spinal nociceptive network: a life span perspective. Pediatr Res. 2021; 91(6):1361-1369. DOI: 10.1038/s41390-021-01638-9. View

18.

Hockley J, Boundouki G, Cibert-Goton V, McGuire C, Yip P, Chan C . Multiple roles for NaV1.9 in the activation of visceral afferents by noxious inflammatory, mechanical, and human disease-derived stimuli. Pain. 2014; 155(10):1962-75. PMC: 4220011. DOI: 10.1016/j.pain.2014.06.015. View

19.

Fidecka S, Pirogowicz E . Lack of interaction between the behavioral effects of ketamine and benzodiazepines in mice. Pol J Pharmacol. 2002; 54(2):111-7. View

20.

Yagi J, Wenk H, Naves L, McCleskey E . Sustained currents through ASIC3 ion channels at the modest pH changes that occur during myocardial ischemia. Circ Res. 2006; 99(5):501-9. DOI: 10.1161/01.RES.0000238388.79295.4c. View